



**K K BARANWAL & ASSOCIATES
CHARTERED ACCOUNTANTS**

**B-62, 2ND FLOOR, SECTOR-8,
DWARKA, NEW DELHI-110075**

Independent Auditors' Report

TO THE MEMBERS OF,

**AMBEY LABORATORIES LIMITED, New Delhi,
(CIN: U74899DL1985PLC020490)**

Report on the Financial Statements

We have audited the accompanying financial statements of **AMBEY LABORATORIES LIMITED, New Delhi**, which comprise the Balance Sheet as at 31st March 2022, the Statement of Profit and Loss for the year ended on that date and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and profit for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our



opinion.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management's for Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. That Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of Financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a



whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant



deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirement

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143, of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143 (3) of the Act, we report that:

We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(a) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

(b) The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.

(c) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(d) On the basis of the written representations received from the directors as on 31st March 2022 taken on record by the Board of Directors, none of the directors are disqualified as on 31st March 2022 from being appointed as a director in terms of Section 164 (2) of the Act.

(e) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in **Annexure B'**.

(f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.



ii. The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

(iv) (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

(d) The Company has not declared or paid any dividend during the year.

Place: New Delhi

Date: 12-09-2022




For K K BARANWAL & ASSOCIATES

Chartered Accountants

(FRN NO.- 024207N)

UDIN: 22514021AXLBVH3539


CA Krishna Kumar

Proprietor

Membership No. -514021

Annexure 'A'

THE ANNEXURE REFERRED TO IN PARAGRAPH 1 OF OUR REPORT ON "OTHER LEGAL AND REGULATORY REQUIREMENTS OF AMBEY LABORATORIES LIMITED "The Company".

We report that:

1. Fixed Asset:

- a. The company has maintained proper records showing full particulars, including quantitative details and situation of its fixed assets.
- b. As explained to us, fixed assets have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification.
- c. The title deeds of immovable properties are held in the name of the company.

2. Inventory:

As explained to us, inventories have been physically verified during the year by the management at reasonable intervals. No material discrepancy was noticed on physical verification of stocks by the management as compared to book records.

3. Loans, Guarantee and Advances given:

According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties listed in the register maintained under Section 189 of the Companies Act, 2013. Consequently, the provisions of clauses iii (a), (b) and (c) of the order are not applicable to the Company.

4. Loans, Guarantee and Advances to Director of Company:

As per explanation given by the management, in respect of loans, investments, guarantees, and security, provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.

5. Deposits:



(Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.

6. Maintenance of costing records:

As per information & explanation given by the management, this clause is not applicable upon the company. Maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013.

7. Deposit of statutory liabilities:

- According to the records of the company, undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees' State Insurance, Income-tax, Sales-tax, Service Tax, Goods and Service tax, Custom Duty, Excise Duty, value added tax, cess and any other statutory dues to the extent applicable, have generally been regularly deposited with the appropriate authorities. According to the information and explanations given to us there were no outstanding statutory dues as on 31st March 2022 for a period of more than six months from the date they became payable, except: TDS Rs. 6.14 lakh and TCS Rs 1.64 Lakh which were remain outstanding as on the date of signing of financial statements.
- According to the information and explanations given to us, there is no amount payable in respect of income tax, service tax, sales tax, customs duty, excise duty, value added tax and cess whichever applicable, which have not been deposited on account of any disputes.

8. Default in repayment of borrowings:

In our opinion and according to the information and explanations given by the management, we are of the opinion that, the Company has not defaulted in repayment of dues to a financial institution, bank, Government or debenture holders, as applicable to the company.

9. Funds raised and utilisation:

Based on our audit procedures and according to the information given by the management, the company has not raised any money by way of initial public offer or further public offer (including debt instruments) or taken any term loan during the year.

10. Fraud and whistle-blower complaints:



10. Fraud and whistle-blower complaints:

According to the information and explanations given to us, we report that no fraud by the company or any fraud on the Company by its officers or employees has been noticed or reported during the year. Hence requirement of filing Form ADT-4 under sub-section (12) of section 143 of the Companies Act, 2013 is not required.

Further, based on the information and explanations given to us there are no whistle blower complaints received by the companies during the year. Therefore, disclosures regarding such complaints are not applicable.

11. Managerial Remuneration:

According to the information and explanations given to us, we report that managerial remuneration has been paid in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act.

12. Nidhi Company:

In our opinion and according to the information and explanation given to us, the Company is not a Nidhi Company. Therefore, provisions of clause 3(xii) of the Order are not applicable to the company.

13. Related Party Transactions:

According to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc. as required by the applicable accounting standards.

14. Internal Audit:

As explained by the management, the company has an internal audit system commensurate with the size and nature of its business.

15. Preferential allotment:

The company has made preferential allotment or private placement of shares during the year under review and the requirement of section 42 and section 62 (1) © of the Companies Act, 2013 have been complied with and the amount raised have been used for the purposes for which the funds were raised.

16. Non Cash Transactions:



According to the information and explanation given to us, the Company has not entered into any non-cash transactions with any of its directors or directors of its holding company, subsidiary company or persons connected with such directors and hence reporting under clause 3(xv) are not applicable to the Company.

17. Cash Losses:

Based on the examination of the financial statements, the Company has not incurred any cash losses during the year & in the immediately preceding financial year. Hence, the provisions of clause 3(xvii) of the Order is not applicable to the Company.

18. Resignation of Statutory Auditors:

As per information provided and explanation given by the management, the previous auditor has resigned due to demerger of the said auditor firm. The resignation is well within the normal cause and no special attention is required for the same.

19. Material uncertainty on meeting liabilities:

On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

20. Transfer to fund specified under Schedule VII of Companies Act, 2013

According to the section 135(1) of the Companies Act, 2013 corporate social responsibility obligation is not applicable to the Company, hence reporting under this clause is not applicable.

21. Registration under RBI act:



According to the information and explanation given to us the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and hence reporting under clauses 3(xxi) of the Order are not applicable to the Company.

For K K BARANWAL & ASSOCIATES

Chartered Accountants

(FRN NO.- 024207N)

UDIN: 22514021AXLBVH3539



CA Krishna Kumar

Proprietor

Membership No. -514021

Date: 12.09.2022

Place: New Delhi

Annexure 'B'

Report on Internal Financial Controls over Financial Reporting

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **AMBEY LABORATORIES LIMITED** ("The Company") as of March 31st 2022 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on



the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

1. Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.



For K K BARANWAL & ASSOCIATES

Chartered Accountants

(FRN NO.- 024207N)

UDIN:22514021AXLBVN3539



CA Krishna Kumar

Proprietor

Membership No. -514021

Date: 12.09.2022

Place: New Delhi

Ambey Laboratories Limited
Balance Sheet as at 31st March, 2022
(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. In Lakh)

	Note	As at March 31, 2022	As at March 31, 2021
EQUITY AND LIABILITIES			
Shareholder's Funds			
Share Capital	3	1,774.94	489.35
Reserves and Surplus	4	(384.79)	(1,968.89)
		<u>1,390.15</u>	<u>(1,479.54)</u>
Non-Current Liabilities			
Long-Term Borrowing	5	1,477.48	3,010.29
Deferred Tax Liability	6	-	-
		<u>1,477.48</u>	<u>3,010.29</u>
Current Liabilities			
Short-Term Borrowing	7	374.32	313.54
Trade payables	8	-	-
Total outstanding dues of micro enterprises and small enterprises		-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises		1,485.20	1,617.92
Other Current Liabilities	9	166.54	192.78
Short Term Provisions	10	163.21	90.68
		<u>2,189.27</u>	<u>2,214.92</u>
Total		<u><u>5,056.90</u></u>	<u><u>3,745.67</u></u>
ASSETS			
Non-Current Assets			
Property, plant and equipment			
Tangible Assets	11(a)	2,411.06	1,457.38
Intangible Assets	11(b)	97.74	127.47
Capital Work-in-progress		-	95.12
Deferred Tax Assets (Net)	6	64.87	9.06
Long Term Loans & Advances	12	-	11.34
		<u>2,573.67</u>	<u>1,700.37</u>
Current Assets			
Inventories	13	1,075.09	873.23
Trade Receivables	14	853.70	692.98
Cash and Cash Equivalents	15	26.91	50.86
Short Term Loan & Advances	16	335.27	280.25
Other Current Assets	17	192.26	147.98
		<u>2,483.23</u>	<u>2,045.30</u>
Total		<u><u>5,056.90</u></u>	<u><u>3,745.67</u></u>

Summary of significant accounting policies 2

The accompanying notes are an integral part of these financial statements.

As per our report of even date

For K K Baranwal & Associates
Chartered Accountants
FRN 0242073

CA Krishna Kumar
Prop.
M.No. 514021
UDIN:22514021AXLBVH3539
Place : New Delhi
Date : 12.09.2022

For and on behalf of the Board of Directors of
Ambey Laboratories Limited
CIN: U74899DL1985PLC020490

Arpit Gupta Archit Gupta
Director Director
DIN: 01876092 DIN: 00378409
Place : Gurgaon Place : Gurgaon

For AMBEY LABORATORIES LIMITED
DIRECTOR
For AMBEY LABORATORIES LIMITED
DIRECTOR

Ambey Laboratories Limited
Statement of Profit and Loss for the year ended 31st March, 2022
(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. In Lakh)

	Note	Year ended March 31, 2022	Year ended March 31, 2021
Income:			
Revenue from operations	18	8,460.07	8,173.94
Other Income	19	51.25	48.79
Total Income		8,511.32	8,222.73
Expenses:			
Cost of material consumed	20	6,991.03	6,462.92
Changes in inventories of work-in-progress, finished goods	21	(101.34)	187.56
Employee benefit expense	22	186.40	185.82
Depreciation and amortization expense	23	297.03	322.22
Finance cost	24	306.11	411.02
Other expenses	25	334.61	373.04
Total		8,013.84	7,942.58
Profit before tax		497.48	280.15
Tax expense:			
Current tax		76.59	46.76
Deferred tax charge/ (benefit)	6	(55.81)	(11.30)
Mat credit entitlement		(76.59)	(46.76)
		(55.81)	(11.30)
Profit/ (loss) for the year		553.29	291.45
Earnings per equity share [Nominal value per share Rs. 100 (previous year Rs.100)]:	27		
Basic earnings per share		31.17	59.60
Diluted earnings per share		31.17	59.60
Summary of significant accounting policies	2		

The accompanying notes are an integral part of these financial statements.

As per our report of even date

For K K Baranwal & Associates
Chartered Accountants
FRN 02/2014

CA Krishna Kumar
Prop.
M.No. 514021
UDIN:22514021AXLBVH3539

Place : New Delhi
Date : 12.09.2022

For and on behalf of the Board of Directors of
Ambey Laboratories Limited
CIN: U74899DL1985PLC020490

Arpit Gupta
Director
DIN: 01876092

Place : Gurgaon

Archit Gupta
Director
DIN: 00378409

Place : Gurgaon

1 Background

Ambey Laboratories Limited ('the Company') is a Company limited by shares domiciled in India, with its registered office situated at Ground Floor, Property No.555 Taria Mohalla, Ghitorni New Delhi-110030. The Company has been incorporated under Companies Act, 1956 (substituted by Companies Act, 2013) on 20 Mar 1985 (CIN U74899DL1985PLC020490). The Company primarily engaged in the business of manufacturing and distribution of home hygiene products under the brand name 'Trishul'.

2 Summary of significant accounting policies

i Basis of Preparation

The financial statements have been prepared in accordance with generally accepted accounting principles in India under the historical cost convention on an accrual basis in compliance with all material aspects of the Accounting Standards (AS) notified under section 133 of the Companies Act 2013, read together with Rule 7 of the Companies (Accounts) Rules 2014. The accounting policies adopted in the preparation of financial statements have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy until now (hitherto) in use with those of previous year.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

ii Use of estimates

The preparation of financial statements requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and disclosure of contingent liabilities, at the end of the reporting period. Although, these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

iii Property, Plant and Equipment - Tangible assets

Tangible assets are stated at cost, less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price, borrowing costs, if capitalization criteria are met and any cost attributable to bringing the assets to its working condition for its intended use which includes taxes, freight, and installation and allocated incidental expenditure during acquisition and exclusive of input tax credit (IGST/CGST and SGST) or other tax credit available to the Company.

When parts of an item of tangible assets have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Subsequent expenditure relating to tangible assets is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

iii Property, Plant and Equipment - Intangible assets

Acquired intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Intangible assets are amortised on a straight line basis over their estimated useful lives. A rebuttable presumption that the useful life of an intangible asset will not exceed ten years from the date when the asset is available for use is considered by the management. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

iv Depreciation on property, plant and equipment

Based on management's evaluation, useful life prescribed in Schedule II of the Companies Act, 2013 represent actual useful life of property, plant and equipment. The Company uses written down value method and has used following useful lives to provide depreciation of different class of its property, plant and equipment.

For AMBEY LABORATORIES LIMITED

M. K. Baranwal
DIRECTOR

For AMBEY LABORATORIES LIMITED
Anil K. Gupta
DIRECTOR



Ambey Laboratories Limited

Notes forming part of the Financial Statements for the year ended 31st March, 2022

(All amounts are in Indian Rupees, unless otherwise stated)

The Company has adopted Schedule II to the Companies Act, 2013 which requires identification and determination of separate useful life for each major component of the property, plant and equipment, if they have useful life that is materially different from that of the remaining asset. (Component Accounting)

Depreciation on addition to tangible assets is provided on pro-rata basis from the date the assets are ready for intended use. Depreciation on sale/discard from tangible assets is provided for upto the date of sale, deduction or discard of tangible assets as the case may be.

Assets costing less than Rs. 5,000 are depreciated @ 100% in the year of put to use.

v Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on Internal/external factors. An impairment loss is recognised wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets' net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital.

After impairment, depreciation/amortization is provided on the revised carrying amount of the asset over its remaining useful life.

vi Foreign currency translation

Initial recognition:

Foreign currency transactions are recorded in the reporting currency by applying the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion:

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when such values were determined.

Exchange differences:

Exchange differences arising on the settlement of monetary items or on reporting the Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognised as income or as expenses in the year in which they occur.

vii Revenue recognition

Revenue is recognised to the extent, that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Revenue from sale of goods

Revenue from sale of goods is recognised when the significant risks and rewards of ownership of the goods are transferred to the buyer.

Interest Income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and applicable interest rate.

Dividend Income

Dividend income on shares of corporate bodies and units of mutual funds is accounted on accrual basis when the Company's right to receive dividend is established.

Revenue from sale of services

Revenue from sale of services are accounted based on stage of completion of assignments, when there is reasonable certainty of its ultimate realisation.



For AMBEY LABORATORIES LIMITED
Ambey
DIRECTOR

For AMBEY LABORATORIES LIMITED
Ambey
DIRECTOR

Ambey Laboratories Limited

Notes forming part of the Financial Statements for the year ended 31st March, 2022

(All amounts are in Indian Rupees, unless otherwise stated)

viii Investment

Non-Current Investment

Non-current investments are investments intended to be held for a period of more than a year. Non-current investments are carried individually at cost less provision for diminution, other than temporary, in the value of such investments.

Current Investment

Current investments are investments intended to be held for a period of less than a year. Current investments are stated at the lower of cost and market value, determined on an individual investment basis.

ix Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with banks. Bank overdrafts are shown within borrowings in current liabilities in balance sheet.

x Inventories

Inventories are valued at lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct cost and related overheads.

Provision of obsolescence on inventories is considered on the basis of management's estimate based on demand and market of the inventories.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

xi Income taxes

Tax expense for the period comprises of current tax, deferred tax and Minimum alternate tax credit considered in determining the net profit or loss for the year.

Current tax

Provision for current tax is recognized on the basis of estimated taxable income for the current accounting year in accordance with the Income-tax Act, 1961.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts, and there is an intention to settle the asset and the liability on a net basis.

Deferred tax

The deferred tax for timing differences between the book and tax profits for the year is accounted for, using the tax rates and laws that have been substantively enacted as of the reporting date.

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets. Deferred tax assets are reviewed at each balance sheet date and are written-down or written up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realised.

At each reporting date, the Company reassesses the unrecognized deferred tax assets, if any.



For AMBEY LABORATORIES LIMITED
[Signature]
DIRECTOR

For AMBEY LABORATORIES LIMITED
[Signature]
DIRECTOR

Minimum alternate tax

Minimum alternate tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the Company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the Statement of Profit and Loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the Company does not have convincing evidence that it will pay normal tax during the specified period.

xii Leases

Operating leases - As a lessee

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to Statement of Profit and Loss on a straight-line basis over the period of lease.

xiii Provisions, Contingent Liability and Contingent Asset

Provisions

The Company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation.

Contingent liabilities

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made.

Contingent assets

Contingent assets are neither recorded nor disclosed in the financial statements.

xiv Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average numbers of equity shares are adjusted for events such as bonus issue, bonus element in the rights issue, share split and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

For AMBEY LABORATORIES LIMITED
M. C. Chugh
DIRECTOR

For AMBEY LABORATORIES LIMITED
Anshu Chugh
DIRECTOR



Ambeey Laboratories Limited
Notes forming part of the Financial Statements for the year ended 31st March, 2022
Note - 3. Share Capital

Particulars	Figures as at the end of		Figures as at the end of previous reporting Period	
	Number of shares	Rs.	Number of shares	Rs.
(a) Authorised				
Equity shares of Rs. 100/- each with voting rights	20.00	2,000.00		7.00
(b) Issued, Subscribed and Paid up				
Equity shares of Rs. 100 each with voting rights	20.00	2,000.00		7.00
	17.75	1,774.94		4.89
Total	17.75	1,774.94		4.89

List of Shareholders holding more than 5% share capital

Name of Shareholders	No. of Shares	%	Value/Share	Total Value
Anil Gupta	7.79	44.00%	100	779.00
Archit Gupta	2.79	15.70%	100	279.00
Arpit Gupta	2.90	16.30%	100	290.00
Achla Gupta	2.26	12.70%	100	226.00
Anil Gupta HUF	1.20	6.70%	100	120.00
TOTAL	16.94	95.40%		1,694.00

Note 3A. Shares Held By Promoters

Sr. No.	Current Reporting Period			% Change during the year
	Promotor's Name	No of shares	% of total shares	
	1 Anil Gupta	7.79	44.00%	255
	2 Archit Gupta	2.79	15.70%	144
	3 Arpit Gupta	2.90	16.30%	153

Sr. No.	Previous reporting Period			% Change during the year
	Promotor's Name	No of shares	% of total shares	
	1 Anil Gupta	2.19	44.81% NA	NA
	2 Archit Gupta	1.15	23.42% NA	NA
	3 Arpit Gupta	1.15	23.42% NA	NA

For AMBEY LABORATORIES LIMITED
DIRECTOR

Ambeey
DIRECTOR




Note- 3B. Statements of Changes In Equity

Balance at the beginning of the current reporting period	Current Reporting Period			Balance at the end of the current reporting period
	Changes in Equity Share Capital due to prior period error	Related Balance at the beginning of the current reporting period	Changes in Equity Share Capital during the current year	
Authorised Capital 7.00 Equity shares Each Rs 100			Authorised Capital Increase by 13.00 Shares	20.00 Equity Shares
Paid Up Capital 4.89 Equity shares Each Rs 100			Paid up capital increased by 12.86 equity sh	17.75 Equity shares

Balance at the beginning of the previous reporting period	Previous reporting Period			Balance at the end of the previous reporting period
	Changes in Equity Share Capital due to prior period error	Related Balance at the beginning of the previous reporting period	Changes in Equity Share Capital during the previous year	
		N/A		

For AMBEY LABORATORIES LIMITED

 DIRECTOR

For AMBEY LABORATORIES LIMITED

 DIRECTOR



Ambey Laboratories Limited
 Notes forming part of the Financial Statements for the year ended 31st March, 2022
 (All amounts are in Indian Rupees, unless otherwise stated)

(Rs. in Lakh)

4 Reserves and surplus	As at	As at
	March 31, 2022	March 31, 2021
Surplus/(deficit) in the Statement of Profit and Loss		
Opening balance	(1,968.89)	(2,260.32)
Add: Profit for the year	553.29	291.45
Add: Prior period adjustment	(19.70)	0.40
Add: Revaluation of land	1,050.00	-
Less : Other adjustment	0.51	(0.42)
Closing balance	<u>(384.79)</u>	<u>(1,968.89)</u>

For AMBEY LABORATORIES LIMITED

M. K. Baranwal
 DIRECTOR

For AMBEY LABORATORIES LIMITED
 Anubhavs
 DIRECTOR



Ambey Laboratories Limited
Notes forming part of the Financial Statements for the year ended 31st March, 2022
(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. in Lakh)

	As at March 31, 2022	As at March 31, 2021
5 Long Term Borrowings		
Secured		
Term Loan from Banks/ Financial Institutions	1,089.77	1,413.48
Vehicle loan (Refer note below)	-	1.98
Unsecured		
Term Loan from Financial Institution	107.04	154.39
Loan for capital assets	-	-
Loan from directors and relatives	142.24	1,299.97
Other long term loans	138.43	140.47
	<u>1,477.48</u>	<u>3,010.29</u>

Note:

1 Secured

(i) Term loan represent the loan from:

- a). Assets Care & Recontraction Enterprise Ltd amounting to Rs. 22,51,00,000 (Principal amount toward the total dues of Rs. 15,50,00,000 to ICICI Bank as on October 16, 2018). It carries interest rate of "1 Base Rate+3%+6%-10%" (Default Rate) for Cash Credit, Term Loan & Developed LC.

Primary security:

Loan from Assets Care & Recontraction Enterprise Ltd secured by:
Exclusive charge on movable assets of the Company.

Collateral security:

Loan from Assets Care & Recontraction Enterprise Ltd are further secured by personal Guarantee of Mr. Anil Gupta, Mr. Archit Gupta, Mr. Arpit Gupta.

2 Unsecured

(i) Term loan represent the business loan from:

- a). Oxyzo Financial Services Pvt Ltd amounting to Rs. 1,00,00,000. It carries interest rate of 18% per annum.
b). Oxyzo Financial Services Pvt Ltd amounting to Rs. 95,00,000. It carries interest rate of 18% per annum.

	As at March 31, 2022	Charge/(benefit) for the year	As at March 31, 2021
6 Deferred tax liability (net)			
Deferred tax liability/(asset)			
Difference between book depreciation and tax depreciation	64.87	55.81	9.06
Total	<u>64.87</u>	<u>55.81</u>	<u>9.06</u>

7 Short term borrowings

Secured

From banks

Current maturities of long-term borrowings

323.71

313.54

Unsecured

Current maturities of long-term borrowings

50.80

Cash credit and overdraft facilities from bank

Total

374.32

313.54

8 Trade payables

Total outstanding dues of micro enterprises and small enterprises

-

-

Total outstanding dues of creditors other than micro enterprises and small enterprises

1,485.20

1,617.92

Total

1,485.20

1,617.92

9 Other current liabilities

Advance from customer

9.61

10.09

Statutory dues payable

60.88

37.33

Payable to employees

50.61

97.09

Other expenses payable

4.54

4.66

Other Current Liabilities

40.90

43.61

Total

166.54

192.78

10 Short term provisions

Provision for Income tax (net of advance tax)

163.21

90.68

Total

163.21

90.68



For AMBEY LABORATORIES LIMITED

[Handwritten Signature]

FOR AMBEY LABORATORIES LIMITED
DIRECTOR

[Handwritten Signature]

Figures For the Current Reporting Period

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Sundry Creditors	1,275.61	10.57	120.70	78.32	1,485.20
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Total					1,485.20

Figures For Previous Reporting Period

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Sundry Creditors	1,402.11	137.54	78.27	0	1,617.92
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Total					1,617.92

For AMBEY LABORATORIES LIMITED
Mulay
 DIRECTOR

For AMBEY LABORATORIES LIMITED
Anil Gupta
 DIRECTOR



Ambeey Laboratories Limited
Notes forming part of the Financial Statements for the year ended 31st March, 2022
(All amounts are in Indian Rupees, unless otherwise stated)

11(a) Property, plant and equipment

(Rs. in Lakhs)

Particulars	Land	Building	Building Temporary Structure	Plant and Machinery	Office equipments	Computers and printers	Furniture & Fixture	Electrical Installation and Equipment	Motor Vehicle	Laboratory Equipment	Total
Own assets:											
Gross block											
Balance as at 31 March 2020	49.50	708.94	-	2,766.19	26.49	17.26	16.09	115.27	65.75	28.63	3,794.12
Additions	-	24.67	-	68.29	2.86	1.17	5.24	-	-	-	102.23
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2021	49.50	733.61	-	2,834.48	29.35	18.43	21.33	115.27	65.75	28.63	3,896.35
Additions	1,050.00	45.58	-	88.19	1.43	0.53	-	35.00	-	-	1,220.73
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2022	1,099.50	779.19	-	2,922.67	30.78	18.96	21.33	150.27	65.75	28.63	5,117.08
Accumulated depreciation											
Balance as at 31 March 2020	-	414.84	-	1,506.75	23.59	16.42	14.49	103.04	56.10	25.78	2,161.01
Depreciation during the year	-	26.67	-	241.93	1.17	0.51	0.84	3.85	2.66	0.36	277.99
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2021	-	441.51	-	1,748.68	24.76	16.93	15.33	106.89	58.76	26.14	2,433.00
Depreciation during the year	-	29.71	-	219.13	1.80	0.87	1.57	11.68	1.92	0.34	267.02
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2022	-	471.22	-	1,967.81	26.56	17.80	16.90	118.57	60.68	26.48	2,706.02
Net block											
Balance as at 31 March 2021	49.50	292.10	-	1,085.80	4.59	1.50	6.00	8.38	6.99	2.59	1,437.45
Balance as at 31 March 2022	1,099.50	307.97	-	954.86	4.22	1.16	4.43	31.70	4.87	2.15	2,411.06

For AMBEY LABORATORIES LIMITED
M. G. G. W. R.
DIRECTOR

For AMBEY LABORATORIES LIMITED
Anil G. R.
DIRECTOR



Ambey Laboratories Limited


Notes forming part of the Financial Statements for the year ended 31st March, 2022

(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. In Lakh)

11(a) Intangible Assets

Particulars	Computer Software	Total
Own assets:		
Gross block		
Balance as at 31 March 2020	190.32	190.32
Additions	-	-
Disposals	-	-
Balance as at 31 March 2021	<u>190.32</u>	<u>190.32</u>
Additions	0.27	0.27
Disposals	-	-
Balance as at 31 March 2022	<u>190.59</u>	<u>190.59</u>
Accumulated depreciation		
Balance as at 31 March 2020	18.60	18.60
Depreciation during the year	44.24	44.24
Disposals	-	-
Balance as at 31 March 2021	<u>62.84</u>	<u>62.84</u>
Depreciation during the year	30.01	30.01
Disposals	-	-
Balance as at 31 March 2022	<u>92.85</u>	<u>92.85</u>
Net block		
Balance as at 31 March 2021	127.48	127.48
Balance as at 31 March 2022	97.74	97.74

For AMBEY LABORATORIES LIMITED

 DIRECTOR

For AMBEY LABORATORIES LIMITED

 DIRECTOR



Ambey Laboratories Limited

Notes forming part of the Financial Statements for the year ended 31st March, 2022
 (All amounts are in Indian Rupees, unless otherwise stated)

(Rs. In Lakh)



Schedule of Fixed Assets as per Income Tax Act, 1961 as on 31st March, 2022

Particulars	Rate Of Dep.	WDV as on 01.04.21	Addition		Sale/ Adj.	Total	Depreciation	WDV as on 31.03.22
			More than 180 days	Less than 180 days				
Plant & Machinery	15%	1037.49	42.31	80.88	-	1,160.68	168.04	992.64
Office Equipments	15%	2.62	0.17	1.26	-	4.05	0.51	3.54
Furniture & Fittings	10%	22.89	-	-	-	22.89	2.29	20.60
Computer & Computer Peripherals	40%	1.31	0.36	0.17	-	1.84	0.70	1.14
Building	10%	554.93	3.56	42.02	-	600.51	57.95	542.56
Computer Software	25%	0.45	0.07	0.20	-	0.72	0.16	0.57
TOTAL		1,619.69	46.47	124.53	-	1,790.69	229.65	1,561.05

Calculation of Deferred Tax

WDV as per Companies Act
 WDV as per Income Tax Act
 Timing Difference

DTA	1,311.56
Last Year DTA	1,561.05
Provision for CY DTA	249.49
	64.87
	9.06
	55.81

For AMBEY LABORATORIES LIMITED

 For AMBEY LABORATORIES LIMITED

 DIRECTOR




Ambey Laboratories Limited


Notes forming part of the Financial Statements for the year ended 31st March, 2022

(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. In Lakh)

	As at March 31, 2022	As at March 31, 2021
12 Long Term loans and advances		
Other long term advances	-	11.34
Total	-	11.34
13 Inventories	As at March 31, 2022	As at March 31, 2021
(Valued at lower of cost and net realizable value, unless stated otherwise)		
Stock-in-trade	1,075.09	873.23
Total	1,075.09	873.23
15 Cash and bank balances	As at March 31, 2022	As at March 31, 2021
Cash and cash equivalents		
Cash on hand	26.24	33.87
Balances with bank on current accounts	0.67	16.99
Total	26.91	50.86
16 Short term loans and advances	As at March 31, 2022	As at March 31, 2021
Advance to suppliers	269.04	222.72
Capital advances	10.30	10.30
Advances to employees	11.58	15.89
Balance with Government authorities	44.35	31.34
Other advances	-	-
Total	335.27	280.25
17 Other current assets	As at March 31, 2022	As at March 31, 2021
Bank deposits with maturity of more than 12 months	1.10	0.10
Imprest	18.01	59.23
Prepaid expenses	4.82	6.46
Mat credit entitlement	123.35	46.76
Security Deposit	44.82	34.52
Other current assets	0.16	0.91
Total	192.26	147.98

For AMBEY LABORATORIES LIMITED

 DIRECTOR

For AMBEY LABORATORIES LIMITED

 DIRECTOR



Note 14 Trade Receivables

Figures For the Current Reporting Period

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	432.51	0.18	0.13		420.88	853.70
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others						-

Figures For Previous Reporting Period

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	271.66	-	-	1.26	420.06	692.98
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others						-

For AMBEY LABORATORIES LIMITED
M. K. Baranwal
 DIRECTOR

For AMBEY LABORATORIES LIMITED
M. K. Baranwal
 DIRECTOR



List of Sundry Debtors

Figures For the Current Reporting Period

Particulars	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years
Advance Micro Fertilizers Pvt. Ltd.	-	-	-	-	64.40
Best Agrochems Pvt. Ltd.	-	-	-	-	59.52
Crystal Crop Protection Pvt. Ltd.	-	-	-	-	8.22
Ichiben Crop Science Ltd.	-	-	-	-	111.50
Shanti Chemtrade Pvt. Ltd.	-	-	-	-	158.80
Sharda Cropchem Limited	0.05	-	-	-	-
S.C. Formulator Co. Ltd.	429.26	-	-	-	-
Sahib Pesticides	-	-	-	-	2.11
GSP Crop Science Pvt. Ltd.	-	-	-	-	1.67
Indo Gulf Crop Science Ltd.	-	-	-	-	9.46
Misc. Bawal Debtors	-	-	-	-	4.39
Omkar Overseas	3.20	-	-	-	-
Bharat Insecticides	-	-	-	-	0.82
Bioagri Laboratories Ltd.	-	-	0.13	-	-
Chemex Internation Ltd.	-	0.18	-	-	-
Total	432.51	0.18	0.13	-	420.88

For AMBEY LABORATORIES LIMITED
M. K. Baranwal
 DIRECTOR

For AMBEY LABORATORIES LIMITED
Anil Kumar
 DIRECTOR



Ambey Laboratories Limited
Notes forming part of the Financial Statements for the year ended 31st March, 2022
(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. In Lakh)

	Year ended 31-Mar-22	Year ended 31-Mar-21
18 Revenue from operations		
Sale of products		
Manufactured goods	8,460.07	8,173.94
Total	8,460.07	8,173.94

	Year ended 31-Mar-22	Year ended 31-03-2021
19 Other income		
Commission income	-	19.72
Interest income	0.58	4.03
Export incentives	28.26	23.21
Foreign exchange fluctuation	20.11	1.83
Other miscellaneous income	2.30	-
Total	51.25	48.79

	Year ended 31-Mar-22	Year ended 31-03-2021
20 Cost of material consumed		
Inventory at the beginning of the year	103.35	421.57
Purchases during the year	6,239.04	5,391.16
Inventory at the end of the year	203.87	103.35
Direct expenses		
Factory Salaries, wages, bonus and other allowances	352.08	363.35
Contribution to provident and other funds	14.55	10.93
Testing expenses	1.49	1.91
Factory Electricity Expenses	155.74	166.43
Manufacturing & freight expenses	328.65	210.92
Total	6,991.03	6,462.92

	Year ended 31-Mar-22	Year ended 31-03-2021
21 Changes in inventories of work-in-progress, finished goods		
Inventory at the beginning of the year		
Finished goods	189.08	423.43
Work-in-progress	580.80	534.01
	769.88	957.44
Inventory at the end of the year		
Finished goods	239.63	189.08
Work-in-progress	631.59	580.80
	871.22	769.88
Total	(101.34)	187.56

	Year ended 31-03-2022	Year ended 31-03-2021
22 Employee benefits expense		
Salaries, wages, bonus and other allowances	119.29	120.73
Staff welfare	41.91	42.29
Directors remuneration	25.20	22.80
Total	186.40	185.82



For AMBEY LABORATORIES LIMITED

M. M. Bhatnagar
DIRECTOR

For AMBEY LABORATORIES LIMITED
Ambey Gyan
DIRECTOR

Ambey Laboratories Limited

Notes forming part of the Financial Statements for the year ended 31st March, 2022

(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. in Lakh)

	Year ended 31-03-2022	Year ended 31-03-2021
23 Depreciation and amortisation expense		
Depreciation on tangible assets [Refer note 11(a)]	267.02	277.98
Depreciation on intangible assets [Refer note 11(b)]	30.01	44.24
Total	297.03	322.22
24 Finance cost		
Interest expense		
On term Loan	305.11	409.53
Bank charges	1.00	1.49
Total	306.11	411.02

For AMBEY LABORATORIES LIMITED
Mullay
DIRECTOR

For AMBEY LABORATORIES LIMITED
Anubh
DIRECTOR



Ambey Laboratories Limited

Notes forming part of the Financial Statements for the year ended 31st March, 2022

(All amounts are in Indian Rupees, unless otherwise stated)

(Rs. In Lakh)


25 Other expenses	Year ended March 31, 2022	Year ended March 31, 2021
Audit remuneration (Refer note below)	0.50	0.50
Advertisement expenses	0.31	0.53
Business promotion expenses	20.98	12.52
Bad debts	-	53.77
Documentation expenses	1.16	1.17
Communication expenses	6.72	3.66
Commission Expenses	17.91	23.01
Research & development Expenditure	-	2.05
Donation expenses	0.01	0.08
Electricity expenses	6.68	8.99
Freight outward	52.76	69.19
Insurance expenses	10.99	6.09
Legal & professional expenses	75.87	26.73
Office expenses	8.69	5.33
Printing & stationery	1.81	1.88
Rates and taxes	16.39	18.65
-Building	0.13	36.66
-Others	12.39	0.53
Rental expenses	83.49	74.92
Travelling and conveyance expenses	8.95	16.14
Vehicle Running & Maintainence	5.82	3.14
Other miscellaneous expenses	3.05	7.50
Total	334.61	373.04


Note :

(a) The following is the break-up of Auditors remuneration (exclusive of GST)

As auditor:

Statutory audit	0.50	0.50
Other matter	-	0.37
Total	0.50	0.87

For AMBEY LABORATORIES LIMITED

 DIRECTOR

For AMBEY LABORATORIES LIMITED

 DIRECTOR



	March 31, 2022	March 31, 2021
26 Expenditure in foreign currency (On Accrual basis)		
Commission expenses	17.49	10.92
Total	17.49	10.92
27 Earnings per share (EPS)		
Profit/ (loss) after tax attributable to equity shareholders	553.29	291.45
Weighted average number of equity shares (In numbers)	17.75	4.89
Nominal value of equity shares (In Rs.)	100.00	100.00
Basic earnings/ (loss) per share (In Rs.)	31.17	59.60
Diluted earnings/ (loss) per share (In Rs.)	31.17	59.60

28 Related party disclosures

In accordance with the requirement of Accounting Standard (AS)- 18 on "Related Party Disclosures" the names of the related parties where control exists / able to exercise significant influence along with the aggregate transactions/year end balances with them as identified and certified by the management are given below:

(a) Names of the related parties and related party relationship

i Key Management Personnel (KMP):

Anil Gupta
Archit Gupta
Arpit Gupta

ii Entities under common control of KMP:

Aromatic Rasayan Pvt Ltd

iii Relatives of KMP:

Rishita Gupta
Achala Gupta
Sarina Gupta

(b) Transaction with related Parties:

	Year ended March 31, 2022	Year ended March 31, 2021
Sale of goods		
Aromatic Rasayan Pvt Ltd	7,052.30	4,094.58
Director Remuneration		
Anil Gupta	8.40	8.40
Archit Gupta	8.40	7.20
Arpit Gupta	8.40	7.20
Salary paid		
Rishita Gupta	4.80	4.80
Achala Gupta	4.80	4.80
Sarina Gupta	4.80	4.80

29 Previous year's figures

Previous year's figures have been regrouped/ reclassified to conform with the current year's classification/ presentation, wherever applicable.

As per our report of even date

For K K Baranwal & Associates
Chartered Accountants
FRN 024207N
UDIN:22514021AXLBVH3539

For and on behalf of the Board of Directors of
Ambey Laboratories Limited
CIN: U74899DL1985PLC020490

CA Krishna Kumar
Prop.
M.No. 514021

Arpit Gupta
Director
DIN: 01876092

Archit Gupta
Director
DIN: 00378409

Place : New Delhi
Date : 12.09.2022

Place : Gurgaon
Place : Gurgaon



For AMBEY LABORATORIES LIMITED
DIRECTOR
For AMBEY LABORATORIES LIMITED
DIRECTOR

Notes to long term borrowings

S.No.	Particulars	Amount
	Secured	
1	Assets Care & Recontraction Enterprise Ltd	1,089.77
		A 1,089.77
	Unsecured	
1	Oxyzo Financial Services Pvt Ltd	54.92
2	Oxyzo Financial Services Pvt Ltd	52.12
		B 107.04
	Loan from directors and relatives	
1	Anil Gupta	66.71
2	Archit Gupta	2.10
3	Arpit Gupta	1.04
4	Achla Gupta	4.69
5	Rishita Gupta	4.55
6	Sarina Gupta	63.15
		C 142.24
	Other long term loans	
1	Bazigar Trading Pvt. Ltd.	4.50
2	D. Mall	16.00
3	Govind Rubber Ltd.	10.00
4	Nova Business Solutions	36.48
5	Rakshit Chemicals Industries Ltd.	61.00
6	S G Art Entertasinment	3.50
7	Sunil Kumar Sultania	6.95
		D 138.43
	Total (A+B+C+D)	1477.48

For AMBEY LABORATORIES LIMITED
Mulay
 DIRECTOR

For AMBEY LABORATORIES LIMITED
Archit Gupta
 DIRECTOR



Ambeey Laboratories Limited

I Title deeds of Immovable Property not held in name of the Company

Relevant line items in the Balance sheets	Descriptions of item of property	Gross carrying Value	Title deeds of immovable Property not held in name of the Company	Whether title deed holder is a promoter, director or relative of promoter/ director or employee of promoter/ director	Property held since which date	Reason for not being held in the name of company
1	As per the management, company do not have any immovable property the title deed of which not held in the name of the company					

Where the Company has revealed its Property, Plant and Equipment, the company shall disclose as to whether the revaluation is based on the valuation by a registered valuer as defined under rule 2 of the Companies (Registered Valuers and Valuation) Rules, 2017

2 During the year, the company has revealed its industrial land.

III where Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013.) either severally or jointly with any other person, that are:

- (a) repayable on demand or
- (b) without specifying any terms or period of repayment

Type of Borrower	Amount of loan and Advance in the nature of Loan outstanding	Percentage to the total Loans and Advances in the nature of loans
Promoters		
3 Directors		
KMPs	NA	NA
Related Parties		

IV Capital Work In Progress (CWIP)

(a) For Capital-work-in progress, following ageing schedule shall be given

Projects in progress Projects temporarily suspended	Amount in CWIP for a period of			Total
	Less than 1 year	1-2 years	2-3 Years	
CWIP				

4 As per the Management, the company do not have any CWIP during the current year

(b) For capital-work-in progress, whose completion is overdue or has exceeded its cost compared to its original plan, following

Projects in progress	To Be Completed in				Total
	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
CWIP					
Project 1	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
Project 2	NIL	NIL	NIL	NIL	NIL

V Intangible assets under development:

(a) For Intangible assets under development

Intangible Assets under Development	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
Project 1	NIL	NIL	NIL	NIL	NIL
Project 2	NIL	NIL	NIL	NIL	NIL



M. M. M. M.

Ambeey Ltd

(b) Intangible assets under development completion schedule

Intangible Assets under Development	To be Completed in			Total
	Less than 1 year	1-2 years	2-3 Years	
7 Project 1	NIL	NIL	NIL	NIL
Project 2	NIL	NIL	NIL	NIL

VI Details of Benami Property held

8 As per Management disclosure, Company do not held any benami property as on 31st March 2022.

9 As per Management disclosure, Company do not have any benami property as on 31st March 2022.

10 Whether the Company has borrowings from banks or financial institutions on the basis of current assets (a) whether quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts. (b) if not, summary of reconciliation and reasons of material discrepancies, if any to be adequately disclosed

11 As per Management disclosure, Company do not have any borrowing against its current assets as on 31st March 2022.

VIII Willful Defaulter

a. Date of declaration as willful defaulter,
b. Details of defaults (amount and nature of defaults),
10 As per Management disclosure, Company neither have declared nor have any willful default as on 31st March 2022.

IX Relationship with Struck off Companies

Where the company has any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956, the Company shall disclose the following details:-

Name of struck off Company	Nature of transactions with struck off Company	Balance outstanding	Relationship with the Struck off company, if any, to be disclosed
	Investments in securities		
	Receivables		
	Payables		
	Shares held by struck-off Company		
	Other outstanding balances (to be specified)		

11 As per the management, no such company has been strucked off. However, they have not been provided any documents for the same.

X Registration of charges or satisfaction with Registrar of Companies

Where any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period, details and reasons thereof shall be disclosed.

12 As per disclosure by the company, there is no such charges or satisfaction yet to be registered with Registrar of Companies.

XI Compliance with number of layers of companies

Where the company has not complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017, the name and CIN of the companies beyond the specified layers and the relationship/extent of holding of the company in such downstream companies shall be disclosed.

XI Ratios

Ratios	Numerator	Denominator	Current Reporting Period	Previous reporting period	% of Change
Debt Equity Ratio	Debt Capital	Shareholder's Equity	1.04	6.79	-5.75
Debt Service coverage ratio	EBITDA-CAPEX (Net)	Debt Service (Int+Prinpal)	0.51	0.27	0.24



Handwritten signature

Handwritten signature

Return on Equity Ratio	Profit for the year	Average Shareholder's Equity	0.31	0.60	-0.28
Inventory Turnover Ratio	COGS	Average Inventory	7.07	5.91	1.17
Trade Receivables turnover ratio	Net Sales	Average trade receivables	10.94	13.77	-2.83
Trade payables turnover ratio	Total Purchases (Fuel Cost + Other Expenses-Closing Inventory-Opening Inventory)	Closing Trade Payables	4.20	3.33	0.87
Net capital turnover ratio	Sales	Working capital (CA-CL)	27.87	-48.19	76.06
Return on Capital employed	Net Profit	Sales	0.0588	0.0343	0.02
Return on Investment	Earnings before interest and tax	Capital Employed	0.2793	0.4515	-0.17
	Net Profit	Investment	0.36	-0.19	0.55

XII Compliance with approved Scheme(s) of Arrangements

Scheme of Arrangements have been accounted for in the books of account of the Company 'in accordance with the Scheme' and 'in accordance with accounting standards' and deviation in this regard shall be explained

13 As per the information by the management, no such arrangement has been made in the year of the audit
XIII Utilisation of Borrowed funds and share premium:

14 As informed by the management, the company has utilised the borrowed fund for running the operation of the company. The company has not any security premium reserve.



[Handwritten signature]
Auditor's Sign